Christopher P. Prior is CEO at INNOVATE BIOPHARMACEUTICALS, INC. (INNT). They have made 5 open-market trades across 1 company since 2018, most recently 2018-11-29.
CIK 0001721749
5 open-market purchases totalling $25K since 2018, never a sale. Across 5 scored buys the stock is down 47.2% at ninety days, and 41.5 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| INNT | 7,009 | $4K |
Shares reported on the most recent Form 4, priced at the 2018-11-29 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 40% | 0% |
| Avg Move | +16.4% | +6.6% | -47.2% |
| Alpha | +17.3% | +10.4% | -41.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INNT | BUY | 2018-11-29 | 2018-11-29 | $2.75 | $14K | -2.2% | -14.1% | -28.3% |
| INNT | BUY | 2018-09-14 | 2018-09-14 | $5.82 | $1K | +23.9% | -5.8% | -54.5% |
| INNT | BUY | 2018-09-12 | 2018-09-13 | $6.13 | $3K | +22.8% | -10.9% | -56.6% |
| INNT | BUY | 2018-08-30 | 2018-08-30 | $5.20 | $2K | +17.0% | +26.9% | -49.3% |
| INNT | BUY | 2018-08-28 | 2018-08-28 | $4.93 | $5K | +20.8% | +37.0% | -47.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.